Heated intraperitoneal chemotherapy (HIPEC) at the time of tumor debulking for ovarian cancer has at least one randomized prospective trial demonstrating benefit in overall survival. There is conflicting data as to the approach and timing of HIPEC. Concerns exist regarding toxicity and complexity of use. Significant heterogeneity exists amongst providers whether HIPEC is even discussed as a treatment option with patients. This session will address the pro's and con's of HIPEC to provide clarity on its current role.
 

Speakers:
Michael McHale, MD
University of California San Diego Health

Chad Michener, MD
Cleveland Clinic

Moderators:
Renata Urban, MD
University of Washington

Susan Zweizig, MD
UMass Memorial Health Care

Recorded on February 24, 2021. 

Not eligible for CE credits. 

Keywords: Chemotherapy, Clinical Practice, HIPEC, ovary, Pharmacology, Journal Club, Surgical- Open